Primaquine Phosphate

CHEMBL43128 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
455.3 g/mol
LogP
Phase
4

A phosphate salt form of primaquine with the same therapeutic properties. An antiparasitic medication used to treat and prevent certain types of malaria, particularly to eliminate the dormant liver stages of Plasmodium vivax and Plasmodium ovale that can cause the infection to relapse weeks or months later.

Peso Molecular

455,3400 g/mol

TPSA

216,00 Ų

Áreas Terapêuticas

Mecanismo de Ação

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc(NC(C)CCCN)c2ncccc2c1.O=P(O)(O)O.O=P(O)(O)O

InChI

InChI=1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)

Molecular Formula

C15H27N3O9P2

HBD / HBA

8 / 12

Ligações Rotacionáveis

6

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A phosphate salt form of primaquine with the same therapeutic properties. An antiparasitic medication used to treat and prevent certain types of malaria, particularly to eliminate the dormant liver stages of Plasmodium vivax and Plasmodium ovale that can cause the infection to relapse weeks or months later.

Disrupts essential metabolic pathways or structural components of parasitic organisms, leading to paralysis, starvation, or death of the parasite.

Yes, Primaquine Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL43128. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6135. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.